Effect of Colchicine in Patients With Myocardial Infarction
Status:
Enrolling by invitation
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Over the past years, a substantial volume of evidence has accumulated identifying
inflammatory processes as key mediators of the deleterious effects of
ischemia/reperfusion-related phenomena in patients presenting with ST-segment-elevation
myocardial infarction (STEMI). Nevertheless, equally impressive is the lack of clinically
applicable therapeutic strategies that could mitigate these processes, thus providing
significant cardioprotection. Despite the well-known fact that inflammation plays an
important role in coronary artery disease development and progression, there have been few
attempts to systematically examine the potential role of anti-inflammatory treatment in this
setting, possibly because of a lack in anti-inflammatory agents without the adverse
cardiovascular safety profile of corticosteroids and nonsteroidal anti-inflammatory drugs.
Colchicine is a substance with potent anti-inflammatory properties, having a unique mechanism
of action, which allows for safe use in patients with cardiovascular disease.
The purpose of the present clinical study is to test the hypothesis that a short course of
treatment with colchicine could lead to reduced major adverse cardiovascular events (MACE) in
acute MI.